Werewolf Therapeutics, Inc.
Clinical trials sponsored by Werewolf Therapeutics, Inc., explained in plain language.
-
New drug WTX-330 shows promise in early trial for tough cancers
Disease control OngoingThis study tests an experimental drug called WTX-330 in about 100 adults with advanced solid tumors or non-Hodgkin lymphoma that hasn't responded to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. Researchers will also monitor si…
Phase: PHASE1, PHASE2 • Sponsor: Werewolf Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 05:54 UTC
-
New drug combo targets tough cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called WTX-124, either alone or combined with pembrolizumab, in 150 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose, while also seeing if the drug …
Phase: PHASE1 • Sponsor: Werewolf Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 04:37 UTC